Latest Conference Articles

Greater Understanding of CLL Pathophysiology Spurs Small Molecules Development

Greater Understanding of CLL Pathophysiology Spurs Small Molecules Development

September 30th 2022, 4:00pm

SOHO Annual Meeting

William Wierda, MD, PhD, will explore the emergence of small molecule–inhibitor targeted therapies.

Using Biology to Determine Type and Duration of Treatment in Waldenström Macroglobulinemia

Using Biology to Determine Type and Duration of Treatment in Waldenström Macroglobulinemia

September 30th 2022, 3:25pm

SOHO Annual Meeting

Jorge J. Castillo, MD, will explore the challenges of managing WM. He will present on September 30, 2022, at 11:04 AM.

Should Small Molecules Be Sequenced or Administered in Combination Regimens in CLL?

Should Small Molecules Be Sequenced or Administered in Combination Regimens in CLL?

September 30th 2022, 3:00pm

SOHO Annual Meeting

During a debate a the SOHO 2022 Annual Meeting, Jennifer R Brown, MD, PhD presented in favor of combining small molecules in CLL. Making the argument for sequencing small molecules in CLL was Anthony Mato, MD.

Many Challenges, Opportunities for CAR T-Cell Therapies in Lymphoma

Many Challenges, Opportunities for CAR T-Cell Therapies in Lymphoma

September 30th 2022, 2:00pm

SOHO Annual Meeting

Sattva S. Neelapu, MD will discuss chimeric antigen receptor T-cell therapy will in lymphoma iduring a session at the SOHO 2022 Annual Meeting.

Novel Agents Gain Ground as CTCL Treatment Landscape Evolves

Novel Agents Gain Ground as CTCL Treatment Landscape Evolves

September 30th 2022, 1:00pm

SOHO Annual Meeting

Novel therapies for cutaneous T-cell lymphoma novel therapies for this patient population are helping to create straightforward management strategies.

CAR T-Cell Therapy Could Replace Auto Transplant in Multiple Myeloma

CAR T-Cell Therapy Could Replace Auto Transplant in Multiple Myeloma

September 30th 2022, 12:00pm

SOHO Annual Meeting

The depth and durability of responses seen with these CAR T-cell therapies in refractory myeloma is unprecedented and raises again the question of the role of up-front autologous stem cell transplant in the era of immune therapies, including CAR T-cell therapies.

Belantamab Mafodotin Induces Deep and Durable Responses in R/R Myeloma

Belantamab Mafodotin Induces Deep and Durable Responses in R/R Myeloma

September 30th 2022, 2:19am

SOHO Annual Meeting

Interim findings from the DREAMM-6 study hint that belantamab mafodotin plus lenalidomide and dexamethasone is effective with tolerable safety in patients with relapsed or refractory multiple myeloma.

Ponatinib and Blinatumomab Demonstrates Durable Responses in PH+ ALL

Ponatinib and Blinatumomab Demonstrates Durable Responses in PH+ ALL

September 29th 2022, 9:56pm

SOHO Annual Meeting

Hagop M. Kantarjian, MD, discusses what experts should know regarding ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Benefits of Disease-Modifying Agents Explored in the Pre-Transplant MPN Setting

Benefits of Disease-Modifying Agents Explored in the Pre-Transplant MPN Setting

September 29th 2022, 8:57pm

SOHO Annual Meeting

Haris Ali, MD, explored the potential role of disease-modifying agents on transplant indications in this setting during the 10th Annual Meeting of the Society of Hematologic Oncology

In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy?

In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy?

September 29th 2022, 6:00pm

SOHO Annual Meeting

With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.